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OBJECTIVES: Diseases are often described and studied as if they
occur in isolation, yet there is increasing recognition of the
complex interrelatedness of diseases and treatment outcomes in
patients with multiple chronic diseases. The objective of this
study was to describe the incremental impact of diseases involv-
ing chronic inﬂammation (chronic obstructive pulmonary disease
(COPD), osteoarthritis (OA) and rheumatoid arthritis (RA)) on
survival when co-occurring with different combinations of other
chronic diseases. METHODS: A cohort aged 55–64 years from
the national database of Veteran’s Affairs was identiﬁed with one
or more of the following conditions: COPD, diabetes, hyperten-
sion, RA, OA, asthma, depression, ischemic heart disease,
dementia, stroke, and cancer. Clusters of mutually exclusive
disease combinations were created and ﬁve-year all-cause mor-
tality rates were calculated. The relative risk of mortality asso-
ciated with additive effect of presence of COPD, OA, and RA in
common disease clusters was estimated. RESULTS: A total of
741,847 persons were identiﬁed (mean age = 59.2yrs [SD = 3.1]).
Five-year mortality rates were lowest among persons with a
single condition and followed a logical progression of higher
mortality rates with more chronic conditions. A major exception
was presence of OA as a co-morbid condition. OA was associ-
ated with a signiﬁcantly lower risk of 5-year mortality compared
to the chronic condition(s) alone: COPD (RR = 0.73 [95% CI,
0.65, 0.81]); ischemic heart disease (0.63 [0.52, 0.76]); hyper-
tension (0.77 [0.71, 0.83]); dementia (0.63 [0.42, 0.93]); depres-
sion (0.65 [0.50, 0.84]); hypertension plus diabetes (0.85 [0.77,
0.93]); and ischemic heart disease plus hypertension (0.83 [0.73,
0.94]). CONCLUSIONS: The association of OA with reduced
rates of ﬁve-year mortality with other chronic diseases is a com-
pelling result. Replicating these ﬁndings in other large popula-
tion-based databases is an important next step in order to begin
exploring possible causative relationships.
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OBJECTIVES: There is a worldwide increase of use of herbal
products but the safety data is often lacking. The use of TU-
HUO-CHI-SHENG-TANG (THCST), which contains trace
amounts of aristolochic acid (AA), raises concern. This study
aimed to actively monitor the safety of THCST used for treat-
ing knee osteoarthritis. METHODS: A multi-center, prospective,
and observational study was designed to apply Good Clinical
Practice to monitor and quantify any adverse event (AE) and
adverse drug reaction (ADR) occurred to the patients who took
THCST ﬁve grams a day for four weeks. Complete blood counts,
liver and kidney function tests, and RBP (retinol binding protein)
and NAG (N-acetyl-b-D glucosaminidase) were also performed
before and after use. Every reported/detected AE were indepen-
dently assessed by site investigators and study nurses in terms of
its severity and causal relationship with the study drug. Subse-
quently, a severe or suspected adverse drug reaction (ADR)
would be submitted to the panel for ﬁnal decision. RESULTS: A
total of 71 eligible subjects were included and 291 AEs reported.
There was no signiﬁcant detectable change of liver and kidney
function. All AEs were either mild or moderate. The most often
reported AEs were rash, cough, abdominal fullness, somnolence,
muscle cramps and diarrhea, with the incidence rates of 14.98,
12.91, 12.91, 11.88, 10.33 and 10.33 per 103 person-days,
accordingly and of 7.98, 6.88, 6.88, 6.33, 5.51 and 5.51 per 103
person-sachets, accordingly. Four AEs were judged to be ADRs,
which included one event each of skin discoloration, ﬂashes,
diarrhea and tachycardia. CONCLUSIONS: The safety proﬁle
of THCST for human use was established to some degree, which
might provide THCST more evidence to become an acceptable
alternative in the treatment of knee osteoarthritis.
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OBJECTIVES: With withdrawal of arthritics painkiller Vioxx
from the market due to reported events of heart attack and
stroke, the risk of Cox2 drugs has been investigated and chal-
lenged. The study is designed to retrospectively evaluate the heart
attack/stroke occurrence of arthritic patients treated with COX2
and other painkillers in the commercially insured outpatient
setting. METHODS: Arthritic patients(n = 7035) who were con-
tinuously enrolled from January 2000 to December 2004 and
had been treated with arthritic painkillers were extracted from
the CDW outpatient data warehouse and grouped into 3 groups:
Vioxx group (n = 2636); Cox2-Vioxx: Cox2 drugs excluding
Vioxx (n = 2520) and Others group: others arthritic drugs (OTC,
Preferential cox2, Salicylate Salts, and NSAIDs, n = 1879). The
adverse events were identiﬁed as patient diagnosis of either heart
attack or stroke in patient visits. Six months were deﬁned as
clearance time period to ensure there was no such adverse event
prior to receiving the drugs. Chi square test and Logistic regres-
sion were used to compare differences among incident rates of
the three groups. RESULTS: Patients with rheumatoid and
osteoarthritis showed statistically signiﬁcant differences (Chi =
Volume 9 • Number 3 • 2006
V A L U E  I N  H E A L T H
Contributed Poster Presentations
A24 © 2006, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/06/A24 A24–A173
